Treats pain of osteoarthritis of the knee(s). ANDA 207714, held by Apotex. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 207714 (Diclofenac Sodium), held by Apotex, was first approved by FDA on May 6, 2022, with 1 approved supplement and 0 published complete response letters.
Diclofenac sodium topical solution is indicated for the treatment of the pain of osteoarthritis of the knee(s).
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 6, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium2% · solution;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 6, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters